Xortx announces appointment of chief technology officer

Calgary, alberta, jan. 20, 2022 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of dr. david macdonald as chief technology officer (cto). dr. macdonald has an over 30-year record of achievement in drug development and leadership in pharma and biotech, achieving critical, value-inflection milestones for those companies.
XRTX Ratings Summary
XRTX Quant Ranking